Ocugen, Inc. 8-K

What Happened

• Ocugen, Inc. filed an 8-K on March 20, 2026 disclosing that an institutional investor partially exercised warrants on March 12, 2026, purchasing 10,000,000 shares of common stock for gross proceeds of $15.0 million.
• This follows a registered direct offering closed in August 2025 under which Ocugen sold 20,000,000 shares and warrants to purchase up to an additional 20,000,000 shares.

Key Details

• Registered direct offering (Aug 2025) originally included 20,000,000 shares and warrants to purchase up to 20,000,000 shares.
• On Mar 12, 2026 the investor exercised warrants for 10,000,000 shares, generating $15.0 million in gross proceeds to Ocugen.
• Ocugen states the proceeds are expected to extend its cash runway into the first quarter of 2027.
• The 8-K includes the company’s customary forward-looking statements cautioning that expectations may change and are subject to risks described in its SEC filings.

Why It Matters

• The $15M infusion provides near-term liquidity for Ocugen and may delay the need for additional financing in the short term.
• Investors should note this is a partial exercise of warrants tied to the August 2025 financing and that the company’s runway projection is forward-looking and subject to risks and uncertainties disclosed in Ocugen’s SEC filings.